GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reported a series of open‑market share purchases by its board leaders in June 2026. Non‑Executive Chair Sir Jonathan Symonds bought 1,550 ordinary shares at £19.3524 each on the London Stock Exchange on 2026-06-19. On 2026-06-22, several Independent Non‑Executive Directors, including Elizabeth McKee Anderson, Charles Bancroft, Anne Beal, Hal Dietz, Jeannie Lee and Vishal Sikka, purchased American Depositary Shares on the New York Stock Exchange at a price of $50.6908 per ADS in individual amounts ranging from 667 to 1,855 ADS.
GSK plc reports purchases of its own ordinary shares between 15 and 19 June 2026 under its existing share buyback programme, executed through Citigroup Global Markets Limited. Daily purchases ranged from 209,874 to 245,840 shares, at volume-weighted average prices between 1,934.67 and 1,971.11 GBp per share.
The purchased shares will be held as treasury shares. Since 11 May 2026, GSK has bought 8,448,125 ordinary shares. After these transactions, it holds 269,826,411 shares in treasury and has 4,046,440,349 ordinary shares in issue, which is also the total number of voting rights.
The company states that, following these purchases, 6.67 per cent of voting rights are attributable to ordinary shares held in treasury, which shareholders can use as the denominator for disclosure calculations under UK transparency rules.
GSK reports that the US FDA has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral options.
The approval is based on the phase III PIVOT-PO trial, where oral tebipenem pivoxil 600 mg achieved a 58.5% overall success rate versus 60.2% for intravenous imipenem-cilastatin 500 mg, meeting the preset non-inferiority margin. Safety was generally similar to comparator carbapenems, with mostly mild to moderate diarrhoea and headache.
cUTIs account for more than 3 million cases annually in the US and over $6 billion in healthcare costs, with treatment failure affecting up to 34% of patients. Tebipenem pivoxil is anticipated to be available to US patients by the end of 2026 and extends GSK’s anti-infectives portfolio under its collaboration with Spero Therapeutics.
GSK plc reports further share repurchases under its existing buyback programme. Between 8 and 12 June 2026, the company, via Citigroup Global Markets Limited, bought a series of ordinary shares of 31¼ pence each on UK exchanges at prices around the high-1,800 to low-2,000 GBp range.
The purchased shares will be held as Treasury shares. Since 11 May 2026, GSK has bought a total of 7,346,236 ordinary shares. After the latest purchases, GSK holds 268,724,522 ordinary shares in treasury and has 4,047,527,077 ordinary shares in issue excluding treasury.
The total number of voting rights is now 4,047,527,077, and GSK states that 6.64 per cent of voting rights are attributable to treasury shares, which investors can use when assessing disclosure thresholds under UK transparency rules.
GSK plc reports that its JAK inhibitor momelotinib has received Orphan Drug Designation from both the US FDA and the EMA for treating VEXAS syndrome, a rare and life-threatening haemato-inflammatory disorder with no approved therapies.
The decision draws on case studies suggesting JAK inhibitors, including momelotinib, may help reduce VEXAS-related symptoms, inflammation and blood complications. A planned phase II/III ATLAS trial will evaluate momelotinib’s efficacy and safety in VEXAS and is intended to support global regulatory submissions as part of a broader haematology development programme.
Momelotinib (Ojjaara/Omjjara) is already approved in the US, EU, UK and Japan for various myelofibrosis indications in adults with anaemia or disease-related symptoms, and has a differentiated mechanism targeting JAK1, JAK2 and ACVR1 signalling pathways.
GSK plc reports that several senior leaders and one person closely associated with a leader acquired small amounts of company stock through its Share Reward Plan. On 2026-06-09, each transaction involved GSK ordinary shares of 31 ¼ pence each, traded on the London Stock Exchange.
Executives including President Europe Lynn Baxter, Chief Financial Officer Julie Brown, and other senior leaders acquired either 14 or 12 ordinary shares each at a price of £18.8393 per share, split between partnership and matching shares. These are routine share plan acquisitions rather than open-market trades.
GSK plc reported that Maya Martinez-Davis, President, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction involved 9.4289 ADS at a price of $50.6400 per ADS on 2026-06-08, executed on the New York Stock Exchange.
GSK plc reported a change in the outside roles of one of its board members. Dr Hal Barron, a Non-Executive Director at GSK, was appointed an Independent Director and Chair of the Nominating and Corporate Governance Committee of Quantinuum Inc. on 4 June 2026.
The company notes this appointment in line with UK Listing Rule 6.4.9R(2). GSK remains a global biopharma company focused on uniting science, technology and talent to get ahead of disease.
GSK plc plans to acquire US oncology company Nuvalent, Inc. in a cash deal valuing the target at $10.6 billion. GSK will launch a tender offer at $124 per share, a 40% premium to Nuvalent’s last closing price and 26% above its 30‑day VWAP.
The transaction adds three lung cancer drugs, including two late‑stage ROS1 and ALK inhibitors under US FDA review with 2026 target decision dates, plus a HER2 inhibitor in phase I. GSK expects low single‑digit core EPS dilution through 2028, accretion to core operating profit in 2027 and to core EPS in 2029, while maintaining 2026 guidance and a 70p dividend.
GSK plc reports further repurchases of its ordinary shares between 1 and 5 June 2026 as part of its existing buyback programme, executed through Citigroup Global Markets Limited. Daily buybacks ranged from 217,096 to 496,356 shares, with volume-weighted average prices between 1,824.85 GBp and 1,922.23 GBp per share.
Since 11 May 2026 the company has purchased 6,233,812 ordinary shares. After the latest transactions, GSK holds 267,612,098 ordinary shares in treasury and has 4,048,628,915 ordinary shares in issue, giving the same number of total voting rights. Treasury shares represent 6.61% of voting rights, a figure shareholders can use when assessing disclosure thresholds.